JP2023541798A5 - - Google Patents
Info
- Publication number
- JP2023541798A5 JP2023541798A5 JP2023512076A JP2023512076A JP2023541798A5 JP 2023541798 A5 JP2023541798 A5 JP 2023541798A5 JP 2023512076 A JP2023512076 A JP 2023512076A JP 2023512076 A JP2023512076 A JP 2023512076A JP 2023541798 A5 JP2023541798 A5 JP 2023541798A5
- Authority
- JP
- Japan
- Prior art keywords
- lysine
- glutamine
- leucine
- acid
- aib
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20315387.9 | 2020-08-19 | ||
| EP20315387 | 2020-08-19 | ||
| PCT/EP2021/072923 WO2022038179A1 (en) | 2020-08-19 | 2021-08-18 | Crf2 receptor agonists and their use in therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026007364A Division JP2026071260A (ja) | 2020-08-19 | 2026-01-20 | Ｃｒｆ２受容体アゴニスト及び治療におけるその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023541798A JP2023541798A (ja) | 2023-10-04 |
| JP2023541798A5 true JP2023541798A5 (enExample) | 2025-09-24 |
| JP7832927B2 JP7832927B2 (ja) | 2026-03-18 |
Family
ID=72615799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023512076A Active JP7832927B2 (ja) | 2020-08-19 | 2021-08-18 | Ｃｒｆ２受容体アゴニスト及び治療におけるその使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20250243255A1 (enExample) |
| EP (2) | EP4199946B1 (enExample) |
| JP (1) | JP7832927B2 (enExample) |
| KR (1) | KR20230051583A (enExample) |
| CN (1) | CN116472053A (enExample) |
| AU (1) | AU2021328673A1 (enExample) |
| CA (1) | CA3192032A1 (enExample) |
| ES (1) | ES2988026T3 (enExample) |
| HR (1) | HRP20240906T1 (enExample) |
| HU (1) | HUE066991T2 (enExample) |
| IL (1) | IL300464A (enExample) |
| IS (1) | IS3063B (enExample) |
| MX (1) | MX2023002087A (enExample) |
| PL (1) | PL4199946T3 (enExample) |
| WO (1) | WO2022038179A1 (enExample) |
| ZA (1) | ZA202301784B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3204051A1 (en) | 2021-01-20 | 2022-07-28 | Brian Lian | Compositions and methods for the treatment of metabolic and liver disorders |
| JP7642830B2 (ja) | 2021-09-15 | 2025-03-10 | バイキング・セラピューティクス・インコーポレイテッド | 代謝及び肝臓障害の処置のための組成物及び方法 |
| EP4234574A1 (en) * | 2022-02-23 | 2023-08-30 | Corteria Pharmaceuticals | Crf2 receptor agonists and their use in therapy |
| WO2025104264A1 (en) | 2023-11-17 | 2025-05-22 | Gubra A/S | Hcrhr2 selective polypeptides |
| TW202544027A (zh) * | 2024-04-19 | 2025-11-16 | 美商紐羅克里生物科學有限公司 | 促皮質素釋放因子受體２（ｃｒｆｒ２）促效劑 |
| WO2025230248A1 (ko) * | 2024-04-30 | 2025-11-06 | 한미약품 주식회사 | Crf2 수용체 작용제와 그 아실화 결합체의 용도 |
| WO2026064495A1 (en) * | 2024-09-20 | 2026-03-26 | Neurocrine Biosciences, Inc. | Chemically modified peptides and use thereof |
| WO2026064486A1 (en) * | 2024-09-20 | 2026-03-26 | Neurocrine Biosciences, Inc. | Chemically modified peptides and use thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008047241A2 (en) * | 2006-10-16 | 2008-04-24 | Conjuchem Biotechnologies Inc. | Modified corticotropin releasing factor peptides and uses thereof |
| JP5721432B2 (ja) | 2007-08-15 | 2015-05-20 | ノボ・ノルデイスク・エー／エス | アミノ酸含有アルキレングリコール反復単位を含むアシル部を有するインスリン |
| HUE032284T2 (en) | 2008-03-18 | 2017-09-28 | Novo Nordisk As | Protease-stabilized, acylated insulin analogues |
| GB201315335D0 (en) | 2013-08-29 | 2013-10-09 | Of Singapore | Amino diacids containing peptide modifiers |
| CN104356224A (zh) | 2014-10-24 | 2015-02-18 | 杭州阿德莱诺泰制药技术有限公司 | 一种制备萨摩鲁泰的方法 |
| JOP20170153A1 (ar) | 2016-07-15 | 2019-01-30 | Lilly Co Eli | نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة |
| WO2019140030A1 (en) * | 2018-01-12 | 2019-07-18 | Eli Lilly And Company | Combination therapy |
-
2021
- 2021-08-18 US US18/021,712 patent/US20250243255A1/en active Pending
- 2021-08-18 IL IL300464A patent/IL300464A/en unknown
- 2021-08-18 WO PCT/EP2021/072923 patent/WO2022038179A1/en not_active Ceased
- 2021-08-18 EP EP21777954.5A patent/EP4199946B1/en active Active
- 2021-08-18 HU HUE21777954A patent/HUE066991T2/hu unknown
- 2021-08-18 HR HRP20240906TT patent/HRP20240906T1/hr unknown
- 2021-08-18 CN CN202180066716.XA patent/CN116472053A/zh active Pending
- 2021-08-18 AU AU2021328673A patent/AU2021328673A1/en active Pending
- 2021-08-18 ES ES21777954T patent/ES2988026T3/es active Active
- 2021-08-18 JP JP2023512076A patent/JP7832927B2/ja active Active
- 2021-08-18 EP EP24179173.0A patent/EP4435001A3/en active Pending
- 2021-08-18 IS IS050392A patent/IS3063B/is unknown
- 2021-08-18 CA CA3192032A patent/CA3192032A1/en active Pending
- 2021-08-18 KR KR1020237009381A patent/KR20230051583A/ko active Pending
- 2021-08-18 MX MX2023002087A patent/MX2023002087A/es unknown
- 2021-08-18 PL PL21777954.5T patent/PL4199946T3/pl unknown
-
2023
- 2023-02-14 ZA ZA2023/01784A patent/ZA202301784B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023541798A5 (enExample) | ||
| HRP20240906T1 (hr) | Agonisti crf2 receptora i njihova primjena u terapiji | |
| PE20231841A1 (es) | Coagonistas de los receptores glp-1 y gip adecuados para el suministro oral | |
| IL262805B1 (en) | CD47 agonist factors for inducing programmed cell death and their use in the treatment of diseases associated with defects in programmed cell death | |
| JP2013515057A5 (enExample) | ||
| JP2005519059A5 (enExample) | ||
| PE20190355A1 (es) | Derivado de glucagon, conjugado del mismo, composicion que comprende el mismo y uso terapeutico del mismo | |
| JP2014510518A5 (enExample) | ||
| JP2006514104A5 (enExample) | ||
| JP2025508820A5 (enExample) | ||
| PE20181299A1 (es) | Derivados de oxintomodulina novedosos y composicion farmaceutica para tratar la obesidad que comprende los mismos | |
| IL276294B2 (en) | Human CD30 ligand antigen-binding proteins | |
| JP2019533722A5 (enExample) | ||
| HRP20140586T1 (hr) | Peptidi za lijeäśenje beta-amiloidoze | |
| JP2012531219A5 (enExample) | ||
| CN106232616A (zh) | 两亲性合成抗菌肽、其药物组合物及其用途 | |
| JP2007535910A5 (enExample) | ||
| JP2023551122A5 (enExample) | ||
| CO5640143A2 (es) | Formulaciones parenterales de un peptido para el tratamiento de lupus eritematoso sistematico | |
| JP2008521795A5 (enExample) | ||
| JP2005516996A5 (enExample) | ||
| JP2020117504A5 (enExample) | ||
| JP2025512515A5 (enExample) | ||
| WO2005123771A3 (en) | Oligomeric peptides and their use for the treatment of hiv infections | |
| JP2024502740A5 (enExample) |